Oral Toxicities With Antibody-Drug Conjugates: What Physicians Should Know

• by

• October 9, 2026

Breast Cancer De-Escalation: Defining When Less Treatment Is Enough

The evolution of breast cancer care is increasingly challenging a long-standing assumption in oncology: that greater treatment intensity necessarily translates into better outcomes.

• by

• October 13, 2026

• 9 min

Author Correction: A first-in-class selective inhibitor of EGFR and PI3K offers a single-molecule approach to targeting adaptive resistance

• by Christopher E. Whitehead, Elizabeth K. Ziemke, Christy L. Frankowski-McGregor, Rachel A. Mumby, June Chung, Jinju Li, Nathaniel Osher, Oluwadara Coker, Veerabhadran Baladandayuthapani, Scott Kopetz, Judith S. Sebolt-Leopold

• October 12, 2026

Comment on “EHA Guidelines on management of chronic lymphocytic leukemia and Richter transformation”

• by Alessandra Tedeschi, Raul Cordoba, Alessandra Ferrajoli, George Follows, Anna Maria Frustaci, Anne Sophie Michallet, Talha Munir, Susan O'Brien, John F. Seymour, Tait Shanafelt, Clemens Martin Wendtner, Pier Luigi Zinzani, Stephan Stilgenbauer

• October 13, 2026